Sio Gene Ther­a­pies posts pos­i­tive PhI/II da­ta in rare pe­di­atric dis­ease, the first read­out since its name change

A lit­tle over a month af­ter a full com­pa­ny re­brand, the Biotech For­mer­ly Known as Ax­o­vant has its first da­ta read­out un­der its new moniker.

Tues­day’s in­ter­im look comes from Sio Gene Ther­a­pies’ GM1 gan­gliosi­do­sis pro­gram, where the ex-Vant says it saw pos­i­tive safe­ty and ef­fi­ca­cy out­comes in a small Phase I/II tri­al. The re­sults mark what CEO Pa­van Cheru­vu hopes can pro­vide a new foun­da­tion in rare pe­di­atric dis­eases as Sio seeks to move past an epic Alzheimer’s fail just a few years ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER